UPDATED: Only Watch charity auction rescheduled for May

Only Watch, a charity auction that raises money for Duchenne Muscular Dystrophy, has been rescheduled for May 10, WatchPro can reveal.

More than 40 brands have allowed their unique watches to be put forward for the sale, including Patek Philippe and F.P. Journe.

The sale will be run by Christie’s auction house in Geneva.

Confirmed brands providing watches for the sale are: ANGELUS x CHÂTEAU ANGELUS — ARTYA – ATELIER DE CHRONOMÉTRIE – BALTIC – BARBIER-MUELLER – BELL & ROSS – BLANCPAIN – BOVET 1822 – BREGUET – BULGARI – CHANEL – CZAPEK GENÈVE – F.P. JOURNE – FREDERIQUE CONSTANT x CHRISTIAAN VAN DER KLAAUW – FURLAN MARRI – GÉRALD GENTA – GRÖNEFELD – H.MOSER x MB&F – HERMÈS – HUBLOT – JAQUET DROZ – KONSTANTIN CHAYKIN – KRAYON – LAURENT FERRIER – LEDERER – LOUIS MOINET – LOUIS VUITTON – LUDOVIC BALLOUARD x BRITTANY NICOLE COX – MAURICE LACROIX – MONTBLANC – MORITZ GROSSMANN – PATEK PHILIPPE – PETERMANN BÉDAT x AUFFRET PARIS – PIAGET – RESERVOIR x TELOS WATCH – RESSENCE – REXHEP REXHEPI – RICHARD MILLE — SINGER REIMAGINED x GENUS – SPEAKE MARIN —SYLVAIN PINAUD – TAG HEUER – TIFFANY & CO. — TRILOBE – URWERK — VOUTILAINEN – ZENITH.

Publication of the digital catalogue of the auction and lots will be on Tuesday, April 16, and there will be an exhibition of the watches at Christie’s Geneva from May 6.

Only Watch was supposed to take place on November 5 last year with 62 brands donating unique watches.

It was postponed after questions were raised about governance of the charity and the research companies it supports.

The Association Monégasque contre les Myopathies (AMM), a charity based in Monaco and operating under the principality’s Prince Albert, was forced to delay the sale until it provided audited information about how $100 million, raised since the first Only Watch auction was held in 2005, is dispersed to researchers and institutions searching for treatments for Duchenne Muscular Dystrophy.

Only Watch was established by Luc Pettavino, who lost his son to DMD. He is also chairman of AMM and a shareholder of SQY Therapeutics, the biggest beneficiary of funds so far, which is researching treatments and running DMD trials.